ArticleTheranostics2017
Nucleolin-targeted Extracellular Vesicles as a Versatile Platform for Biologics Delivery to Breast Cancer.
Article in Theranostics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 112 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
112 citing papers in PubMed, 2 syntheses or guidelines pooled it, 181 citations in OpenAlex.
- Extracellular vesicles: powerful candidates in nano-drug delivery systems.Drug delivery and translational research · 2024Pooled it
- Biodistribution of extracellular vesicles following administration into animals: A systematic review.Journal of extracellular vesicles · 2021Pooled it
- Engineered exosomes for breast cancer immunotherapy: Emerging strategies and translational potential.Biochemistry and biophysics reports · 2026Review
- Hit the bull's eye: Engineered extracellular vesicles for targeted therapy.Bioactive materials · 2026Review
- Extracellular vesicles in targeted drug delivery: from biological functions to surface engineering.Molecular biomedicine · 2026Review
- Review
- Exosome-mediated post-transcriptional oncogene regulation as a novel cancer therapeutic strategy.Discover oncology · 2026Review
- Human endogenous retrovirus envelope proteins alter extracellular vesicle cellular interactions and biodistribution.bioRxiv : the preprint server for biology · 2026Article
- Advances in Intranasal Delivery of Exosomes for Central Nervous System Disorders.Molecular neurobiology · 2025Review
- Immune-based cancer therapies: mechanistic insights, clinical progress, and future directions.Journal of the Egyptian National Cancer Institute · 2025Review
- Emerging Strategies for Cargo Loading and Engineering of Extracellular Vesicles for Breast Cancer Treatment.Nanomaterials (Basel, Switzerland) · 2025Review
- Extracellular Vesicles in cancer: from isolation and characterization to metastasis, drug resistance, and clinical applications.BMC cancer · 2025Review
- Extracellular vesicles: the "Trojan Horse" within breast cancer host microenvironments.Molecular cancer · 2025Review
- Methods and Challenges in Purifying Drug-Loaded Extracellular Vesicles.Journal of extracellular vesicles · 2025Review
- Bioengineered extracellular vesicles: The path to precision medicine in liver diseases.Liver research (Beijing, China) · 2025Review
- Extracellular vesicles in triple-negative breast cancer: current updates, challenges and future prospects.Frontiers in molecular biosciences · 2025Review
- The signature of extracellular vesicles in hypoxic breast cancer and their therapeutic engineering.Cell communication and signaling : CCS · 2024Review
- Basic Guide for Approaching Drug Delivery with Extracellular Vesicles.International journal of molecular sciences · 2024Review
- Extracellular Vesicles as Drug Delivery System for Cancer Therapy.Pharmaceutics · 2024Review
- Aptamer-functionalized triptolide with release controllability as a promising targeted therapy against triple-negative breast cancer.Journal of experimental & clinical cancer research : CR · 2024Article
52 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Small interfering RNAs (siRNA)/microRNAs (miRNA) have promising therapeutic potential, yet their clinical application has been hampered by the lack of appropriate delivery systems. Herein, we employed extracellular vesicles (EVs) as a targeted delivery system for small RNAs. EVs are cell-derived small vesicles that participate in cell-to-cell communication for protein and RNA delivery. We used the aptamer AS1411-modified EVs for targeted delivery of siRNA/microRNA to breast cancer tissues. Tumor targeting was facilitated via AS1411 binding to nucleolin, which is highly expressed on the surface membrane of breast cancer cells. This delivery vesicle targeted let-7 miRNA delivery to MDA-MB-231 cells
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.